SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

Home・Akcijų sąrašas・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

162.25 -2.08

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

161.6

Max

165.4

Pagrindiniai rodikliai
By Trading Economics
Pajamos	41M 88M
Pardavimai	-11M 762M
P/E Sektoriaus vid.	56.752 57.018
Pelnas, tenkantis vienai akcijai	1.17
Pelno marža	11.569
Darbuotojai	10,456
EBITDA	26M 225M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+41.3% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-3B 15B
Ankstesnė atidarymo kaina	164.33
Ankstesnė uždarymo kaina	162.25

Naujienos nuotaikos

By Acuity

17%

83%

31 / 439 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

202.7 / 211.7 Palaikymas ir pasipriešinimas

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 23:58; UTC

Uždarbis

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026-05-07 22:57; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026-05-07 23:52; UTC

Uždarbis

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026-05-07 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-07 23:39; UTC

Rinkos pokalbiai

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026-05-07 23:28; UTC

Rinkos pokalbiai

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026-05-07 23:11; UTC

Uždarbis

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026-05-07 23:06; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026-05-07 23:05; UTC

Uždarbis

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026-05-07 23:04; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026-05-07 23:02; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026-05-07 23:00; UTC

Rinkos pokalbiai

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026-05-07 22:42; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026-05-07 22:33; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 22:32; UTC

Uždarbis

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie: 68% of FY Income From International >MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026-05-07 22:29; UTC

Uždarbis

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026-05-07 22:26; UTC

Uždarbis

Macquarie to End Share Buyback Extended in November>MQG.AU

2026-05-07 22:25; UTC

Uždarbis

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

41.3% į viršų

12 mėnesių prognozė

Vidutinis 233 EUR 41.3%

Aukščiausias 262 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Sartorius Stedim Biotech. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

31 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.